Egetis Therapeutics Past Earnings Performance
Past criteria checks 0/6
Egetis Therapeutics's earnings have been declining at an average annual rate of -29.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 19% per year.
Key information
-29.8%
Earnings growth rate
9.8%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | -19.0% |
| Return on equity | -59.9% |
| Net Margin | -567.5% |
| Next Earnings Update | 03 May 2024 |
Recent past performance updates
Recent updates
Here's Why We're Not Too Worried About Egetis Therapeutics' (STO:EGTX) Cash Burn Situation
May 26
We're Keeping An Eye On Egetis Therapeutics' (STO:EGTX) Cash Burn Rate
Dec 21Will Egetis Therapeutics (STO:EGTX) Spend Its Cash Wisely?
Jun 07Is Egetis Therapeutics AB (publ) (STO:EGTX) Trading At A 30% Discount?
Jan 19Egetis Therapeutics AB (publ) (STO:EGTX) Is Expected To Breakeven In The Near Future
Mar 22What Type Of Returns Would Egetis Therapeutics'(STO:EGTX) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Feb 15What You Need To Know About Egetis Therapeutics AB (publ)'s (STO:EGTX) Investor Composition
Jan 20
Egetis Therapeutics AB (publ) (STO:EGTX) Insiders Increased Their Holdings
Dec 24Analyst Forecasts For PledPharma AB (publ) (STO:PLED) Are Surging Higher
Dec 03When Will PledPharma AB (publ) (STO:PLED) Breakeven?
Dec 03Revenue & Expenses BreakdownBeta
How Egetis Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 58 | -327 | 170 | 0 |
| 30 Sep 23 | 31 | -319 | 141 | 0 |
| 30 Jun 23 | 24 | -286 | 117 | 0 |
| 31 Mar 23 | 22 | -240 | 91 | 0 |
| 31 Dec 22 | 23 | -194 | 74 | 0 |
| 30 Sep 22 | 20 | -148 | 61 | 0 |
| 30 Jun 22 | 21 | -113 | 52 | 0 |
| 31 Mar 22 | 42 | -114 | 48 | 0 |
| 31 Dec 21 | 38 | -104 | 45 | 0 |
| 30 Sep 21 | 40 | -147 | 40 | 0 |
| 30 Jun 21 | 36 | -153 | 38 | 0 |
| 31 Mar 21 | 33 | -155 | 35 | 0 |
| 31 Dec 20 | 41 | -178 | 32 | 0 |
| 30 Sep 20 | 53 | -127 | 33 | 0 |
| 30 Jun 20 | 56 | -134 | 34 | 0 |
| 31 Mar 20 | 39 | -127 | 36 | 0 |
| 31 Dec 19 | 83 | -61 | 37 | 0 |
| 30 Sep 19 | 77 | -61 | 35 | 0 |
| 30 Jun 19 | 77 | -48 | 34 | 0 |
| 31 Mar 19 | 82 | -46 | 32 | 0 |
| 31 Dec 18 | 28 | -85 | 31 | 0 |
| 30 Sep 18 | 31 | -95 | 30 | 0 |
| 30 Jun 18 | 24 | -103 | 30 | 0 |
| 31 Mar 18 | 14 | -91 | 27 | 0 |
| 31 Dec 17 | 14 | -88 | 24 | 0 |
| 30 Sep 17 | 0 | -67 | 21 | 0 |
| 30 Jun 17 | 0 | -48 | 19 | 0 |
| 31 Mar 17 | 0 | -44 | 19 | 0 |
| 31 Dec 16 | 0 | -38 | 20 | 0 |
| 30 Sep 16 | 0 | -36 | 19 | 0 |
| 30 Jun 16 | 0 | -39 | 19 | 0 |
| 31 Mar 16 | 0 | -39 | 18 | 0 |
| 31 Dec 15 | 0 | -44 | 18 | 0 |
| 30 Sep 15 | 0 | -53 | 28 | 0 |
| 30 Jun 15 | 0 | -53 | 26 | 0 |
| 31 Mar 15 | 0 | -54 | 19 | 0 |
| 31 Dec 14 | 0 | -48 | 19 | 0 |
| 30 Sep 14 | 0 | -38 | 6 | 0 |
| 30 Jun 14 | 0 | -31 | 6 | 0 |
| 31 Mar 14 | 0 | -24 | 10 | 0 |
| 31 Dec 13 | 0 | -26 | 6 | 0 |
| 30 Sep 13 | 0 | -27 | 16 | 0 |
Quality Earnings: EGTX is currently unprofitable.
Growing Profit Margin: EGTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EGTX is unprofitable, and losses have increased over the past 5 years at a rate of 29.8% per year.
Accelerating Growth: Unable to compare EGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EGTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: EGTX has a negative Return on Equity (-59.92%), as it is currently unprofitable.